Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for cancer cachexia in incurable upper gastrointestinal adenocarcinoma
ISRCTN51456701Phase 3Completed
- Sponsor
- Portsmouth Hospitals University NHS Trust
- Start
- Oct 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) comparing Thalidomide with Placebo (2 arms). Primary endpoint: Attenuation of weight loss. Started Oct 2005; status: completed.
02
Drugs
thalidomide
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on ISRCTN51456701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51456701.